Dr. Kiaei is Associate Professor and leading ALS researcher with extensive experience in therapeutic development and pre-clinical drug discovery in neurodegenerative diseases. He has identified druggable targets for ALS and conducted therapeutic tests on promising drug candidates for ALS. As the founder of RockGen, he is dedicated to developing an effective drug for ALS and other neurodegenerative diseases. He leads the mission of RockGen and is deeply involved in the experimental design, implementation, and daily supervision of all aspects of the projects at RockGen.
Dr. Cudkowicz is the Director of the Healey Center for ALS, Chief of Neurology at Mass General, and the Julieanne Dorn Professor at Harvard Medical School. On this advisory role at RockGen, Dr. Cudkowicz leverages over three decades of research and clinical activities in taking care of ALS patients and running clinical trials, therapeutic studies to stop ALS. She is one of the founders of the Northeast ALS Consortium and brought innovations to accelerate the development of treatments for people with ALS, including the first antisense oligonucleotide treatment for ALS and adaptive platform trial designs. Dr. Cudkowicz is Principal Investigator of the Clinical Coordination Center for the NINDS Neurology Network of Excellence in Clinical Trials. She is a member of AAP, NAM, and received the American Academy of Neurology Sheila Essay ALS award, the Pinnacle Award from the Boston Chamber of Commerce.
Dr. Sharifi is a Pharmacist, (First Moscow State Medical University) and he earned his MPhil and Ph.D. degrees in computational chemistry at Medway School of Pharmacy, the University of Kent (England).
In 2015, he was invited to join the US-FDA as a postdoctoral fellow at Biochemical Toxicology and Systems Biology divisions. In 2017, Dr. Sharifi was recruited by Spektron Systems, LLC., (a drug discovery company) which advanced the company with drug-design and computational chemistry approaches to improve potency, selectivity, and ADME properties while minimizing the toxicological risk of novel drug candidates.
Dr. Bennett is a drug discovery consultant and biotech entrepreneur with a focus on preclinical drug optimization and development, inflammation and autoimmunity, cell and molecular biology. He worked for the Upjohn Company, and then Signal Pharmaceuticals, later Celgene, for 20 years and was involved in multiple projects including several currently active in the 3 phases of clinical assessment.
Dr. Bush is a world-renowned neurobiologist and researcher in the field of neurodegenerative diseases. He is the director of Melbourne Dementia Research Center at the Florey Institute of Mental Health, University of Melbourne, Australia. Dr. Bush has co-founded Prana Biotechnology. He is a proprietor at Eucalyptus Biosciences, Pty Ltd.
Dr. Crooks is an internationally renowned medicinal chemist. He is a Professor and Chairman of the Department of Pharmaceutical Sciences, at the University of Arkansas for Medical Sciences, Little Rock, AR, USA. Dr. Crooks has over 35 years of experience in drug chemistry, synthesis, and development. He has over 200 patents to his name and established or co-founded six drug discovery companies. He is the senior vice President of Chemistry at Mitochon Pharmaceuticals.
Dr. Das is a Professor at the Long Island University in New York. He is adjunct faculty at Weill Cornell Medicine, Icahn School of Medicine at Mount Sinai in New York.
He is a medicinal chemist and expert in pharmacological sciences. He has 28 patents and published 89 seminal scientific articles. Dr. Das's training background and experience started with postdoctoral training at MIT and Harvard Medical School and academic career experience at renowned institutions in the USA.
Dr. Varughese is a professor in the Department of Physiology and Biophysics, College of Medicine, the University of Arkansas for Medical Sciences. His laboratory focuses on the structure elucidation of protein molecules using crystallographic techniques. Additionally, he uses structure-based computational techniques to identify novel therapeutic compounds for various targets.
Dr. Jerry A. Darsey is a Professor in the Department of Chemistry at the University of Arkansas at Little Rock. He is the inventor or co-inventor on seven patents and has published over 150 articles. His research interests are primarily in computer modeling techniques of atomic and molecular systems for the elucidation of their chemical and physical properties, but also interested in bioinformatics and medical applications. His research in drug design uses techniques pioneered in his laboratory that involve artificial intelligence procedures and quantum mechanical simulations.